MAP Kinase Inhibitor - p38/RK MAP Kinase Inhibitor - Autophagy inducer

SB202190, a close relative of SB203580, is widely used to assess the physiological roles of p38α and p38β MAPKs.

Recent studies have identified other protein kinases, including GAK, CK1 and RIP2, that are potently inhibited by SB202190 (as well as SB203580) [1].
Further, SB202190 was shown to induce autophagic vacuoles through cross-inhibition of the PI3K/mTOR pathway [2].


Working concentration: 1-60 μM
CAS number:
Molecular weight:
30 mg/ml in DMSO provides a yellow solution
>98% (UHPLC)


• 5 mg SB202190 provided lyophilized

SB202190 is shipped at room temperature. Store lyophilized product at -20°C. Lyophilized product is stable for 1 year when properly stored.


1. Bain J. et al., 2007. The selectivity of protein kinase inhibitors: a further update. Biochem J. 408(3):297-315.

2. Menon MB. et al., 2011. SB202190-induced cell type-specific vacuole formation and defective autophagy do not depend on p38 MAP kinase inhibition. PLoS One. ;6(8):e23054.


Recent articles using InvivoGen SB202190



Description MAP Kinase Inhibitor
Cat. Codetlrl-sb90
Unit Size5 mg
Price For price or distributor address,
please select your country
Disclaimer: Our products are provided for research purpose only. Commercial applications may require licensing from third parties.
Note that the sequence of available ORFs provided by InvivoGen can differ from a given reference Genbank record due to genetic variations and/or alternative splicing. Customers should verify that the version of a gene sold by InvivoGen is suitable for the customer needs.
Copyrights © 2011-2016 InvivoGen. All Rights Reserved. Reproduction of any materials from this site is strictly forbidden without permission for commercial use. Nonprofit use for non-commercial research and educational purposes is permitted, citation should include the URL "".